Anticancer drugs can induce cardiotoxicity; the dilated cardiomyopathy secondary to chemotherapy is more insidious than various cardiomyopathies: 40% of the patients under anthracyclines treatment manifest ventricular arrhythmias, 5% of them manifest left ventricular systolic dysfunction and Congestive Heart Failure. For these patients at high cardiotoxic risk it is therefore very important to prevent cardiovascular damage.
Risk Factors and Prevention
Exclusive access for EAPC Silver Members
Want to have access to these how-to articles?
Become an EAPC Silver Member.
Our mission: To reduce the burden of cardiovascular disease.